Analysts see limited Lantus impact from Tresiba's Indian launch
This article was originally published in Scrip
Analysts are predicting slow growth and a minimal impact on sales of key competitor Sanofi's Lantus (insulin glargine) from the launch of Novo Nordisk's ultra-long acting once-daily insulin Tresiba (insulin degludec) on the Indian market, at least initially.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.